Repurposing neurological drugs for brain cancer therapeutics: A systematic approach to identify charged molecules for affinity-based local drug delivery systems
Abstract
Treatment of glioblastoma (GBM) presents significant challenges due to its high degree of heterogeneity and poor prognosis. Recurrence of the malignancy is frequent even after the standard treatment, including surgery, radiotherapy, and chemotherapy with temozolomide. Drug repurposing offers a cost-effective strategy to identify new treatments, while affinity-based local delivery systems could provide controlled release of therapeutics within the tumor resection cavity. The aims of this study are two-fold. Firstly, to categorize currently available neurological therapeutics according to their charge and suitability for use with affinity-based drug delivery systems. Secondly, to systematically search and evaluate the evidence for anticancer and/or anti-glioblastoma activity for potentially being repurposed/repositioned. The 'neurology/psychiatry' category of the Broad Institute Drug Repurposing Hub (468 compounds) was screened for chemical suitability and anticancer efficacy. Charge, lipophilicity, solubility at pH 7.4 were calculated using Chemicalize. A systematic search for the anticancer efficacy of the charged compounds was carried out via the following databases: PubMed, Scopus, Sci-Finder, Ovid via Medline, Cochrane and ClinicalTrial.gov. Among the 468 compounds, 283 were identified as charged at physiological pH. Notably, 146 charged candidates were found to have anticancer activity, of which 91 showed promising activity against at least one type of brain neoplasm. A…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
- Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial
- Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial
- Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.